ESR1 and breast carcinoma: Although approximately 75% of breast cancer patients with expression of estrogen receptor (ER+) can be treated by endocrine therapy, there are about 15–20% of breast cancer patients with TNBC cells that do not express the above markers, whose treatment options are limited.